Synexus Acquires ClinPharm
Synexus has agreed to acquire Leipzig based ClinPharm and will complete the acquisition in January 2010. This deal will increase the number of Synexus’ Dedicated Research Centres to 26 in nine countries, strengthening its European reach.
Synexus is a multi-national company focused on the recruitment and running of clinical trials at its own Dedicated Research Centres. While it has a network of research centres in Central and Eastern Europe, this acquisition will add eight research centres in Germany. It will strengthen Synexus’ Central and Eastern Europe portfolio of centres in Poland, Hungary and Bulgaria with additional sites in Austria and Ukraine. Synexus now has research centres in Western, Central and Eastern Europe, South Africa and Asia.
The ClinPharm acquisition will increase Synexus’ total patient population reach to over 30 million patients; an increase of 50 per cent globally and 100 per cent across Europe. ClinPharm also brings considerable additional therapy area experience to Synexus.
"In order to keep pace with the market’s demands it is necessary for us to increase our infrastructure and patient reach. ClinPharm provided the ideal opportunity as they have considerable presence in Western, Central and Eastern Europe and also understand the way we work,” said Synexus Chief Executive Michael Fort.
The deal will be finalised in January 2010 after ClinPharm’s year end. ClinPharm’s founding CEO, Hans-Detlev Stahl MD, Ph.D. (Melb). F.R.A.C.P joins Synexus as European Medical Director.
“It was a natural fit to team up with Synexus. We know each other very well and our geographic coverage is totally complementary. Together we are much stronger and I look forward to helping the new company with further expansion which delivers real benefits to our clients in pharma,” said Dr Stahl.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
